Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3H2184
Thu, 07.10.2021
Epigenomics AG
Epigenomics AG: EVP of Finance Albert Weber leaves the Company
Berlin (Germany) and San Diego, CA (U.S.A.), October 7, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Executive Vice President Finance Albert Weber will resign from his position as member of the Executive Board of Epigenomics AG as of [ … ]
Mon, 13.09.2021
Epigenomics AG
NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA
Press Release
Epigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 million
Berlin, September 13, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the [ … ]
Thu, 02.09.2021
Epigenomics AG
New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations
The availability of blood based mSEPT9 tests, such as Epi proColon(R), increased the rate of testing to 93.5%, from 12.6% with fecal immunochemical testing (FIT) in prior years
Epi proColon cu [ … ]
Tue, 24.08.2021
Epigenomics AG
NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA
Press Release / Advertising
Epigenomics AG: Securities prospectus for the issuance of a mandatory convertible bond in the amount of up to EUR 16.5 million approved by BaFin
Berlin, Germany, August 24, 2021 - Epigen [ … ]
Wed, 11.08.2021
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Six Months of 2021
Berlin (Germany) and San Diego, CA (U.S.A.), August 11, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2021.
OPERATIONAL DEVELOPMENTS
Epigenomics AG has two options [ … ]
Wed, 12.05.2021
Epigenomics AG
Press release
Epigenomics AG Reports Financial Results for the First Quarter of 2021
Berlin (Germany) and San Diego, CA (U.S.A.), May 12, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2021.
Financial key figures
Product revenue in the first quarter [ … ]
Tue, 27.04.2021
Epigenomics AG
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA.
Press release
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
Berlin, 27 April 2021 - On 27 April 2021, the Executive Boa [ … ]
Tue, 20.04.2021
Epigenomics AG
Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024
Berlin (Germany) and San Diego (U.S.A.), April 20, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that convertible bonds with a nominal value of EUR 4,357,606.00 have been converted i [ … ]
Tue, 06.04.2021
Epigenomics AG
Study reported in BMC Gastroenterology demonstrates significantly better performance characteristics of Epigenomics' liver cancer panel compared to the current standard of care for the early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis
The Epigenomics next generation sequencing (NGS) liver cancer panel plus alpha-f [ … ]
Wed, 27.01.2021
Epigenomics AG
Epigenomics AG: Dr. Garces transitions to Company Advisor
Berlin (Germany) and San Diego, CA (USA), January 27, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Dr. Jorge Garces, President and Chief Scientific Officer is resigning as an Executive Board member effective January 31, 2021. Dr. Garces [ … ]